Posted on

Enlivex Announces $400,000,000 Private Placement

Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) — Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of ordinary shares (or ordinary share equivalents in lieu thereof) at a price of $5.00 per share for subscription amounts funded in U.S. dollars, USDT or USD Coin and $6.00 per share for subscription amounts funded in RAIN tokens, the $5.00 price representing a premium of 17.4% and the $6.00 price representing a premium of 40.8%, in each case to the closing price of the ordinary shares on July 27, 2026, for expected aggregate gross proceeds of approximately $400,000,000 (funded in U.S. dollars, USDT, USD Coin, RAIN tokens or a combination thereof), before deducting offering expenses (the “Transaction”). The investor has elected to fund the purchase price using RAIN tokens, which election may be changed at any time prior to closing. Enlivex intends to use net proceeds from the private placement in furtherance of its treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum, while continuing to advance Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.

By sf-admin
Posted on

Rocket Doctor AI Inc. Announces Non-Brokered Private Placement of Unsecured Convertible Debentures

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States 

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States

By sf-admin
Posted on

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (“Clearmind” or “Company”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, recently announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of AUD.

By sf-admin
Posted on

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) — Digital Currency X Technology Inc. (Nasdaq: DCX) (“DCX” or the “Company”), a digital asset treasury management company, today announced that DexTrader, the on-chain data platform of the Company , has completed comprehensive product and strategic upgrades. The overhaul includes reconstruction of underlying data architecture, expansion of omnichain data capabilities and optimization of user service frameworks. Concurrently, the platform announced its revised strategic focus: it intends to target the niche market of digital asset information and data services for token-based derivatives, yield instruments and collateralized assets. By pre-emptively building industry data infrastructure, DexTrader hopes to establish a solid foundation for product iteration and market leadership in the future.

By sf-admin
Posted on

Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687

Copenhagen, Denmark, 28 July 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the dosing of the first patient in its Phase 2a trial evaluating AT7687, the Company’s first-in-class Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist, in combination with semaglutide for the treatment of people with obesity and type 2 diabetes.

By sf-admin
Posted on

Ultrasonic Aspirator Market Size Projected to Reach USD 376.32 Million by 2035 | SNS Insider

The U.S. Ultrasonic Aspirator Market is projected to reach USD 118.90 Million by 2035, while Europe is expected to reach USD 107.39 Million, supported by increasing adoption of ultrasonic surgical devices and precision surgical technologies. 

The U.S. Ultrasonic Aspirator Market is projected to reach USD 118.90 Million by 2035, while Europe is expected to reach USD 107.39 Million, supported by increasing adoption of ultrasonic surgical devices and precision surgical technologies.

By sf-admin
Posted on

City Electric Supply (CES) reports strong fiscal year results across North America for the seventh consecutive year

CES, a top 10 electrical wholesale distributor across North America, announced a successful fiscal year highlighted by strong financial performance, leadership promotions, and operational expansion. 

CES, a top 10 electrical wholesale distributor across North America, announced a successful fiscal year highlighted by strong financial performance, leadership promotions, and operational expansion.

By sf-admin